Industry Bulletins | March 16, 2018
New Study Finds Wearable Electrocardiogram Monitoring Patch Can Detect Atrial Fibrillation Earlier & More Efficiently Than Routine Care
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced the results of a home-based clinical trial that showed wearing a continuous electrocardiogram (ECG) monitoring patch can detect atrial fibrillation earlier and more efficiently than routine care. The one-year study was conducted in collaboration with Scripps Translational Science Institute, Aetna, and iRhythm Technologies, Inc.
Atrial Fibrilation (AFib)—which impacts about six million Americans—puts individuals at a much greater risk of stroke, making early detection of AFib significant for the health of individuals. As up to 30 percent of AFIb cases go undiagnosed until a life-threatening complication . . .